Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVM0704
- Development stage
- Preclinical
- Lead developer
- AVM Biotechnology
- Modality
- Small Molecules
01
Overview
AVM0704 is a preclinical-stage small molecule drug being developed by AVM Biotechnology. It is designed to stimulate hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC) to promote the formation of new blood cells. The primary therapeutic goal of AVM0704 is to reduce the clinical requirement for blood transfusions and granulocyte-colony stimulating factor (G-CSF) treatments in patients with hematologic deficiencies. Unlike the company's lead candidate, AVM0703, AVM0704 does not induce an immune reset or mobilize bispecific immune cells, focusing instead on direct stem cell stimulation for hematopoiesis.
Beyond the preview
Go deeper on AVM0704.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVM0704.